#Ireland #Dublin #Jazz Pharmaceuticals #Chimerix #dordaviprone

Jazz Pharmaceuticals Completes Acquisition of Chimerix

On April 21, 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) proudly announced the successful acquisition of Chimerix, Inc. in a deal valued at approximately $935 million in cash. This strategic move aims not only to bolster Jazz's oncology portfolio but also to address pressing healthcare needs among patients suffering from rare diseases.

Chimerix has been integrated as a wholly-owned subsidiary, and with this acquisition, Jazz seeks to enhance its capabilities in developing innovative therapies. According to Bruce Cozadd, the chairman and CEO of Jazz, the inclusion of Chimerix aligns perfectly with their mission to deliver transformative medicines to patients.

Introducing Dordaviprone

A key asset gained through this acquisition is dordaviprone, a first-in-class small molecule designed to target H3 K27M-mutant diffuse glioma. This therapy is currently under Priority Review by the U.S. Food and Drug Administration (FDA), and it could be groundbreaking as it might become the first approved treatment for patients with this specific mutation. The Prescription Drug User Fee Act (PDUFA) action date is set for August 18, 2025, sparking high hopes within the oncology community.

Dordaviprone represents not merely a novel treatment approach but also a critical opportunity for commercial success if approved. Jazz aims to accelerate the timeline for making this therapy available to patients, with plans for potential market introduction as early as the latter half of this year.

The therapy arises from innovative research and the ongoing Phase 3 ACTION trial, which assesses its effectiveness in patients newly diagnosed with and non-recurrent H3 K27M-mutant diffuse glioma following radiation treatment. This expansion into first-line therapeutic settings could significantly impact the management of this challenging condition.

Transaction and Integration Details

Details regarding the acquisition indicate that Jazz's tender offer for Chimerix's outstanding shares concluded on April 17, 2025. The accepted offer was $8.55 per share, in cash, reflecting Jazz's commitment to ensuring stakeholder value throughout this transition. The merger led to the continuous existence of Chimerix as an indirect wholly-owned subsidiary of Jazz

This acquisition not only contributes to a richer product pipeline but also aligns with Jazz’s strategic focus on rare diseases, highlighting its patient-centric mission. The integration of Chimerix's experienced team with Jazz’s existing structure is expected to further enhance their ability to deliver essential therapies to patients worldwide.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is dedicated to innovating treatments that can transform the lives of patients with serious illnesses. Headquartered in Dublin, Ireland, the company operates globally and possesses a diverse therapeutic portfolio encompassing oncology and neuroscience. Jazz Pharmaceuticals is on a mission to overcome barriers faced by patients with limited treatment options.

The forward-looking statements surrounding this acquisition underline Jazz’s commitment to addressing unmet medical needs and advancing patient care. While the landscape of regulatory approvals remains unpredictable, the prospects of dordaviprone signal a positive trajectory for both Jazz and the patients it aims to serve. The future might hold transformations in the treatment of rare diseases, led by effective therapies like dordaviprone, as Jazz continues to prioritize advancement in medically challenged areas.

For up-to-date information, you can visit Jazz Pharmaceuticals’ official website at www.jazzpharmaceuticals.com.